Experimental treatments for human transmissible spongiform encephalopathies: Is there a role for pentosan polysulfate?

Expert Opinion on Biological Therapy

Volumn 7, Issue 5, 2007, Pages 713-726

  Rainov, N G ^a,b   Tsuboi, Y ^c   Krolak Salmon, P ^d   Vighetto, A ^d   Doh ura, K ^e  

^a KLINIKUM AUGSBURG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c FUKUOKA UNIVERSITY   (Japan)

^d HÔPITAL NEUROLOGIQUE   (France)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gerstmann Straussler Scheinker syndrome; Pentosan polysulfate; Prion disease; Quinacrine; Sporadic Creutzfeldt Jakob disease; Transmissible spongiform encephalopathy; Variant Creutzfeldt Jakob disease

Indexed keywords

4' IODOESORUBICIN; ACETYLSALICYLIC ACID; ALOXISTATIN; AMPHOTERICIN B; CHLOROQUINE; CHLORPROMAZINE; CLOPIDOGREL; CONGO RED; DAPSONE; DEXTRAN; DEXTRAN SULFATE; DIETHYLAMINOETHYLDEXTRAN; FLUPIRTINE; GROWTH HORMONE; HEPARIN; MEMANTINE; MEPACRINE; MS 8209; PENTOSAN POLYSULFATE; PHTHALOCYANINE DERIVATIVE; PLACEBO; PORPHYRIN; PRION PROTEIN; RECOMBINANT PROTEIN; SURAMIN; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD BRAIN BARRIER; CANCER; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FATAL FAMILIAL INSOMNIA; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HUMAN; IMMUNOCHEMISTRY; KURU; LIVER DYSFUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; MALARIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRION DISEASE; RETICULOENDOTHELIAL SYSTEM; REVIEW; SEIZURE; SIDE EFFECT; SKIN PIGMENTATION; SUBDURAL EFFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; CREUTZFELDT-JAKOB SYNDROME; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; HUMANS; INJECTIONS, INTRAVENTRICULAR; PENTOSAN SULFURIC POLYESTER; PRION DISEASES; TREATMENT OUTCOME;

RODENTIA;

EID: 34248180644     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.5.713     Document Type: Review

References (89)

1. Sc) molecules and are devoid of nucleic acids. The paper highlights the unique features of prions and differentiates them from all other transmissible pathogens.
2. PRUSINER SB: Prions. Proc. Natl. Acad. Sci. USA (1998) 95:13363-13383. An updated review of the features of infectious prions, focusing on prion disease presentations and clinical manifestations. This paper is one of the first to mention strategies for the prevention and treatment of prion disorders.
3. BRANDNER S, ISENMANN S, RAEBER A et al.: Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature (1996) 379:339-343.
4. CLARKE AR, JACKSON GS, COLLINGE J: The molecular biology of prion propagation. Philos. Trans. R. Soc. Lond. B Biol. Sci. (2001) 356:185-195.
5. CAUGHEY B: Prion protein conversions: insight into mechanisms, TSE transmission barriers and strains. Br. Med. Bull. (2003) 66:109-120.
6. HUANG Z, PRUSINER SB, COHEN FE: Scrapie prions: a three-dimensional model of an infectious fragment. Fold. Dis. (1996) 1:13-19.
7. DELEAULT NR, LUCASSEN RW, SUPATTAPONE S: RNA molecules stimulate prion protein conversion. Nature (2003) 425:717-720.
8. BROWN DR, SCHMIDT B, KRETZSCHMAR HA: Role of microglia and host protein in neurotoxicity of a prion protein fragment. Nature (1996) 380:345-347.
9. BROWN DR, KRETZSCHMAR HA: Microglia and prion disease: a review. Histol. Histopathol. (1997) 12:883-992.
10. REZAIE P, LANTOS PL: Microglia and the pathogenesis of spongiform encephalopathies. Brain Res. Brain Res. Rev. (2001) 35:55-72.
11. BROWN DR: Prion prorein peptide neurotoxicity can be mediated by astrocytes. J. Neurochem. (1999) 73:1105-1113.
12. RAEBER AJ, RACE RE, BRANDNER S et al.: Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J. (1997) 16:6057-6065.
13. GIESE A, BROWN DR, GROSCHUP MH, FELDMANN C, HAIST I, KRETZSCHMAR HA: Role of microglia in neuronal cell death in prion disease. Brain Pathol. (1998) 8:449-457.
14. HEPPNER FL, AGUZZI A: Prion diseases. In: Nature Encyclopedia of Life Sciences. Nature Publishing Group, London, UK (2007) http://www.els.net/ [doi:10.1038/npg.els.0000428.
15. KUBLER E, OESCH B, RAEBER AJ: Diagnosis of prion diseases. Br. Med. Bull. (2003) 66:267-279.
16. KNIGHT R: Creutzfeldt-Jakob disease: clinical features, epidemiology and tests. Electrophoresis (1998) 19:1306-13010.
17. GAMBETTI P, PARCHI P, PETERSEN RB, CHEN SG, LUGARESI E: Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features. Brain Pathol. (1995) 5:43-51.
18. BROWN P, PREECE M, BRANDEL JP et al.: Iatrogenic Creutzfeldt-Jakob disease ar the millennium. Neurology (2000) 55:1075-1081.
19. SMITH PG: The epidemics of bovine spongiform encephalopathy and variant CJD; current status and future prospects. Bull. World Health Organ. (2003) 81:123-130.
20. BROWN P, BRANDEL JP, PREECE M, SATO T: Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology (2006) 67:389-393.
21. MEDORI R, TRITSCHLER HJ, LEBLANC A et al.: Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N. Engl. J. Med. (1992) 326:444-449.
22. FIORINO AS: Sleep, genes and death: fatal familial insomnia. Brain Res. Brain Res. Rev. (1996) 22:258-264.
23. LIBERSKI PP, BUDKA H: Gerstmann-Straussler-Scheinker disease. I. Human diseases. Folia Neuropathol. (2004) 42(Suppl. B):120-140.
24. WILL RG, IRONSIDE JW, ZEIDLER M et al.: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet (1996) 347:921-925. One of the first publications (authored by the UK CJD surveilance unit in Edinburgh) to identify a new form of CJD, the new variant CJD (vCJD), in the UK. The authors raised the possibility that vCJD may be causally linked to BSE.
25. BRUCE ME, WILL RG, IRONSIDE JW et al.: Transmission to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature (1997) 389:498-501. The first report that the infectious agent from BSE cattle produces a characteristic pattern of disease in mice that is retained after experimental passage through a variety of intermediate species. The paper also provides the first direct evidence that prion disease may be transmitted between species.
26. c accumulation in vCJD and characteristic thalamus and midbrain damage caused by severe neuronal loss and gliosis.
27. IRONSIDE JW, HEAD MW: Neuropathology and molecular biology of variant Creutzfeldt-Jakob disease. Curr. Top. Microbiol. Immunol. (2004) 284:133-159.
28. SPENCER MD, KNIGHT RSG, WILL RG: First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. Br. Med. J. (2002) 324:1479-1482. A comprehensive review of the early clinical features of vCJD based on the findings of the national surveillance system for CJD in the UK for the first 100 cases of vCJD.
29. WADSWORTH JD, HILL AF, BECK JA, COLLINGE J: Molecular and clinical classification of human prion disease. Br. Med. Bull. (2003) 66:241-254.
30. MÜLLER WE, LAPLANCHE JL, USHIJIMA H, SCHRODER HC: Novel approaches in diagnosis and therapy of Creutzfeldt Jakob disease. Mech. Ageing Dev. (2000) 16:193-218.
31. HEAD MW, IRONSIDE JW: Inhibition of prion-protein conversion: a therapeutic tool? Trends Microbiol. (2000) 8:6-8.
32. LOVE R: Old drugs to treat new variant Creutzfeldt-Jakob disease. Lancet (2001) 358:563.
33. GILCH S, SCHATZL HM: Promising developments bringing prion diseases closer to therapy and prophylaxis. Trends Mol. Med. (2003) 9:367-369.
34. TREVITT CR, COLLINGE J: A systematic review of prion therapeutics in experimental models. Brain (2006) 129:2241-2265. A comprehensive review of published data on experimental approaches to prion therapeutics, focusing on antibodies to physiological and pathological prion isoforms and their therapeutic use.
35. KOCISKO DA, CAUGHEY B, MORREY JD, RACE RE: Enhanced antiscrapie effect using combination drug treatment. Antimicrob. Agents Chemother. (2006) 50:3447-3449.
36. MCKENZIE D, KACZKOWSKI J, MARSH R, AIKEN J: Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection. J. Virol. (1994) 68:7534-7536.
37. DEMAIMAY R, RACE R, CHESEBRO B: Effectiveness of polyene antibiotics in treatment of transmissible spongiform encephalopathy in transgenic mice expressing Syrian hamster PrP only in neurons. J. Virol. (1999) 73:3511-3513.
38. ADJOU KT, DEMAIMAY R, DESLYS JP et al.: MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replicarion and PrPres accumulation in Syrian hamster scrapie. J. Gen. Virol. (1999) 80:1079-1085.
39. CAUGHEY B, RACE RE: Potent inhibition of scrapie associared PrP accumulation by Congo Red. J. Neurochem. (1992) 59:768-771.
40. CASPI S, HALIMI M, YANAI A, SASSON SB, TARABOULOS A, GABIZON R: The anti-prion activity of Congo red. Putative mechanism. J. Biol. Chem. (1998) 273:3484-3489.
41. TAGLIAVINI F, MCARTHUR RA, CANCIANI B et al.: Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science (1997) 276:1119-1122.
42. MANUELIDIS L, FRITCH W, ZAITSEV I: Dapsone to delay symptoms in Creutzfeldt-Jakob disease. Lancet (1998) 352:456.
43. GILCH S, WINKLHOFER KF, GROSCHUP MH et al.: Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. EMBO J. (2001) 20:3957-3966.
44. SHYNG SL, LEHMANN S, MOULDER K, HARRIS D: Sulfated glycans stimulate endocytosis of the cellular isoform of the prion prorein PrPc in cultured cells. J. Biol. Chem. (1995) 270:30221-30229.
45. PRIOLA SA, RAINES A, CAUGHEY WS: Porphyrin and phthalocyanine antiscrapie compounds. Science (2000) 287:1503-1506.
46. PEROVIC S, PERGANDE G, USHIJIMA H, KELVE M, FORREST J, MULLER WE: Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Neurodegeneration (1995) 4:369-374.
47. PEROVIC S, SCHLEGER C, PERGANDE G et al.: The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1. Eur. J. Pharmacol. (1994) 288:27-33.
48. OTTO M, CEPEK L, RATZKA P et al.: Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology (2004) 62:714-718.
49. DOH-URA K, IWAKI T, CAUGHEY B: Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol. (2000) 74:4894-4897.
50. KORTH C, MAY BC, COHEN FE, PRUSINER SB: Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. USA (2001) 98:9836-9841.
51. TURNBULL S, TABNER BJ, BROWN DR, ALLSOP D: Quinacrine acts as an antioxidant and reduces the toxicity of the prion peptide PrP106-126. Neuroreport (2003) 14:1743-1745.
52. COLLINS SJ, LEWIS V, BRAZIER M, HILL AF, FLETCHER A, MASTERS CL: Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann. Neurol. (2002) 52:503-506.
53. BARRET A, TAGLIAVINI F, FORLONI G et al.: Evaluarion of quinacrine treatment for prion diseases. J. Virol. (2003) 77:8462-8469.
54. MARTINEZ-LAGE JF, RABANO A, BERMEJO J et al.: Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. Surg. Neurol. (2005) 64:542-545.
55. HAIK S, BRANDEL JP, SALOMON D et al.: Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology (2004) 63:2413-2415.
56. NAKAJIMA M, YAMADA T, KUSUHARA T et al.: Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord. (2004) 17:158-163.
57. DIRINGER H, EHLERS B: Chemoprophylaxis of scrapie in mice. J. Gen. Virol. (1991) 782:457-460.
58. CAUGHEY B: Protease-resistant PrP accumulation and scrapie agent replication: a role for sulphated glycosoaminoglycans? Biochem. Neurodegen. Disord. (1994) 22:163-167.
59. CAUGHEY B, BROWN K, RAYMOND GJ, KATZENSTEIN GE, THRESHER W: Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red. J. Virol. (1994) 68:2135-2141.
60. CAUGHEY B, RAYMOND G: Sulfated polyanion inhibition of scrapie associated PrP accumulation in cultured cells. J. Virol. (1993) 67:643-650. One of the early papers on the effects of sulfated glycans on PrP metabolism in scrapie-infected neuroblastoma cells, which investigates the effects of PPS, among other substances. The authors identify prophylactic and therapeutic effects of sulfated polyanions and hypothesise that these may be due to inhibition of PrP accumulation.
61. PEREZ M, WANDOSELL F, COLACO C, AVILA J: Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment. Biochem. J. (1998) 335:369-374.
62. FARQUHAR C, DICKINSON A: Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before of after infection. J. Gen. Virol. (1986) 67:463-473. One of the first reports on the effects of polysulfated sugar molecules (such as DS500) on susceptibility of mice to scrapie.
63. EHLERS B, DIRINGER H: Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J. Gen. Virol. (1984) 65:1325-1330.
64. KIMBERLIN RH, WALKER CA: Pathogenesis of experimental scrapie. Ciba Found. Symp. (1988) 135:37-62.
65. LADOGANA A, CASACCIA P, INGROSSO L et al.: Sulphate polyanions prolong the incubation period of scrapie infected hamsters. J. Gen. Virol. (1992) 73:661-665.
66. FARQUHAR C, DICKINSON A, BRUCE M: Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet (1999) 353:117.
67. DOH-URA K, ISHIKAWA K, MURAKAMI-KUBO I et al.: Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J. Virol. (2004) 78:4999-5006. The first preclinical study of the therapeutic efficacy of direct PPS infusion into the brains of transgenic mice intracerebrally infected with 263K scrapie agent. The authors suggest that intraventricular PPS infusion might be useful in the treatment of TSEs in humans. This publication laid the foundation of the clinical application of PPS in humans.
68. DAWES J, PROWSE CV, PEPPER DS: Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay. Thromb. Res. (1986) 44:683-693.
69. DAWES J, PEPPER DS: Human vascular endothelial cells catabolise exogenous glycosaminoglycans by a novel route. Thromb. Haemost. (1992) 67:468-472.
70. MCGREGOR IR, DAWES J, PEPPER DS: Metabolism of sodium pentosan polysulphate in man measured by a new competitive binding assay for sulphated polysaccharides - comparison with effects upon anticoagulant activity, lipolysis and platelet A-granule proteins. Thromb. Haemost. (1985) 53:411-414.
71. SIE P, ALBAREDE JL, ROBERT M et al.: Tolerance and biological activity of pentosan polysulphate after intramuscular or subcutaneous administration for ten days in human volunteers. Thromb. Haemost. (1986) 55:86-89.
72. MULHOLLAND SG, HANNO P, PARSONS CL, SANT GR, STASKIN DR: Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. Urology (1990) 35:552-558.
73. TARDY-PONCET B, TARDY B, GRELAC F et al.: Pentosan polysulfate induced thrombocytopaenia and thrombosis. Am. J. Haematol. (1994) 45:252-257.
74. EMMETT CJ, STEWART GR, JOHNSON RM, ASWANI SP, CHAN RL, JAKEMAN LB: Distribution of radioiodinated recombinant human nerve growth factor in primate brain following intracerebroventricular infusion. Exp. Neurol. (1996) 140:151-160.
75. GILL SS, PATEL NK, HOTTON GR et al.: Direct brain infusion of glial cell line-derived neurotrophic facror in Parkinson's disease. Nat. Med. (2003) 9:589-595.
76. CORNFORD EM: The blood-brain barrier, a dynamic regulatory inrerface. Mol. Physiol. (1985) 7:219-260.
77. NEUWELT EA: Mechanisms of disease: the blood-brain barrier. Neurosurgery (2004) 54:131-142.
78. KROLL RA, NEUWELT EA: Outwitting the blood-brain barrier for therapeutic purposes: osmoric opening and other means. Neurosurgery (1998) 42:1083-1100.
79. KEMPER EM, BOOGERD W, THUIS I, BEIJNEN JH, VAN TELLINGEN O: Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat. Rev. (2004) 30:415-423.
80. PAKULSKI C, DYBKOWSKA K, DROBNIK L: [Brain barriers. Part II. Blood/cerebrospinal fluid barrier and cerebrospinal fluid /brain tissue barrier], Neurol. Neurochir. Pol. (1998) 32:133-139.
81. FOSSAN G, CAVANAGH ME, EVANS CA et al.: CSF-brain permeability in the immature sheep fetus: a CSF-brain barrier. Brain Res. (1985) 350:113-124.
82. CZOSNYKA M, CZOSNYKA Z, MOMJIAN S, PICKARD JD: Cerebrospinal fluid dynamics. Physiol. Meas. (2004) 25:R51-R76.
83. FENSTERMACHER JD, GHERSI-EGEA JF, FINNEGAN W, CHEN JL: The rapid flow of cerebrospinal fluid from ventricles to cisterns via subarachnoid velae in the normal rat. Acta Neurochir. Suppl. (1997) 70:285-287.
84. ABBOTT NJ: Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. (2004) 45:545-552.
85. TODD NV, MORROW J, DOH-URA K et al.: Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J. Infect. (2005) 50:394-396. The first report of cerebroventricular administration of PPS in a patient with vCJD.
86. PARRY A, BAKER I, STACEY R, WIMALARATNA S: Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. J. Neurol. Neurosurg. Psychiatry (2007) (In Press).
87. WHITTLE IR, KNIGHT RS, WILL RG: Unsuccessful intraventricular pentosan polysulphate trearmenr of variant Creutzfeldt-Jakob disease. Acta Neurochir. (2006) 148:677-679.
88. http://www.ctu.mrc.ac.uk/studies/cjd.asp Medical Research Council, Clinical Trials Unit (MRC CTU). PRION-1: Randomised trial of quinacrine in human prion disease.
89. http://www.mrc.ac.uk/Utilities/Documentrecord/index.hrm?d=MRC003453 Intraventricular pentosan polysulphate in human prion disease - a study of experience in the United Kingdom (issued 1 June 2006).